<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8">
<meta name="Generator" content="Microsoft Word 15 (filtered medium)">
<!--[if !mso]><style>v\:* {behavior:url(#default#VML);}
o\:* {behavior:url(#default#VML);}
w\:* {behavior:url(#default#VML);}
.shape {behavior:url(#default#VML);}
</style><![endif]--><style><!--
/* Font Definitions */
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:"Times New Roman \(Body CS\)";
panose-1:2 2 6 3 5 4 5 2 3 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0in;
margin-bottom:.0001pt;
font-size:12.0pt;
font-family:"Calibri",sans-serif;}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:#0563C1;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:#954F72;
text-decoration:underline;}
span.EmailStyle17
{mso-style-type:personal-compose;
font-family:"Calibri",sans-serif;
color:windowtext;}
span.apple-converted-space
{mso-style-name:apple-converted-space;}
.MsoChpDefault
{mso-style-type:export-only;
font-family:"Calibri",sans-serif;}
@page WordSection1
{size:8.5in 11.0in;
margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
{page:WordSection1;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]-->
</head>
<body lang="EN-US" link="#0563C1" vlink="#954F72">
<div class="WordSection1">
<p class="MsoNormal"><span style="font-size:11.0pt;color:black"><br>
<o:p></o:p></span></p>
<div align="center">
<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" width="600" style="width:6.25in">
<tbody>
<tr>
<td style="padding:0in 0in 0in 0in">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Arial",sans-serif"><img width="600" height="171" style="width:6.25in;height:1.7812in" id="Picture_x0020_2" src="cid:image001.png@01D9B638.100AFE40" alt="Dissertation Defense Announcement at the Cullen College of Engineering"></span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<div align="center">
<table class="MsoNormalTable" border="0" cellspacing="0" cellpadding="0" style="background:white">
<tbody>
<tr>
<td style="padding:30.0pt 15.0pt 7.5pt 15.0pt">
<p class="MsoNormal" align="center" style="text-align:center;line-height:21.0pt">
<span style="font-size:18.0pt;color:#C8102E"> <b>Analytics Approaches to Design Diabetic Retinopathy Screening Policies </b> </span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="text-align:center;line-height:15.0pt">
<b><span style="font-size:13.5pt;color:black">Poria Dorali</span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="mso-margin-top-alt:auto;margin-bottom:3.75pt;text-align:center;line-height:16.5pt">
<span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black"> July 20, 2023; 10:00 AM – 12:00 PM (CDT)</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="mso-margin-top-alt:auto;text-align:center;line-height:16.5pt">
<span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black">Location: E214 Engr. Bldg. 2 </span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="mso-margin-top-alt:auto;margin-bottom:3.75pt;text-align:center;line-height:16.5pt">
<b><span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black">Committee Co-Chairs:</span></b><span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black"><br>
Gino Lim, Ph.D | Taewoo Lee, Ph.D</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" align="center" style="mso-margin-top-alt:auto;margin-bottom:15.0pt;text-align:center;line-height:16.5pt">
<b><span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black">Committee Members:</span></b><span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black"><br>
Ying Lin, Ph.D | Christina Weng, MD, MBA | Ashish Deshmukh, Ph.D | Jiming Peng Ph.D</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
</td>
</tr>
<tr>
<td style="padding:0in 15.0pt 15.0pt 15.0pt">
<p class="MsoNormal" style="mso-margin-top-alt:auto;margin-bottom:11.25pt;line-height:16.5pt">
<b><span style="font-family:"Arial",sans-serif;color:#C8102E">Abstract</span></b><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;margin-bottom:11.25pt;line-height:16.5pt">
<span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black">Diabetic retinopathy (DR) is the leading cause of blindness for working-age adults in the US. Over 60% of patients with type II diabetes and 90% of patients with type I diabetes develop
DR within 20 years of diagnosis. Routine comprehensive screening examinations have proved effective in detecting early stages of DR and timely treatment can prevent up to 98% of DR-related vision loss. However, only 50-60% of diabetic patients adhere to the
current annual screening guidelines. Recently, teleretinal imaging (TRI) has emerged as an accessible screening tool for patients with limited access. However, there exists no well-established guideline that incorporates TRI-based screening for such patients.</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
<p class="MsoNormal" style="mso-margin-top-alt:auto;margin-bottom:11.25pt;line-height:16.5pt">
<span style="font-size:10.5pt;font-family:"Arial",sans-serif;color:black">In this thesis, we study a multi-pronged analytics approach to quantify and evaluate the advantages and limitations of TRI compared with traditional clinic-based screening (CS) and propose
new screening policies for patients with limited access to eye care. First, we develop a simulation model that examines the health and cost benefits of various routine CS and TRI-based DR screening policies at different time intervals for various types of
diabetic patients. Additionally, we identify patient subgroups who would truly benefit from TRI in terms of health benefits and cost savings Second, we develop a partially observable Markov decision process (POMDP) model to generate personalized DR screening
recommendations that exploit the dynamic interaction of TRI and traditional screening based on each patient’s unique health-related and behavioral factors. Lastly, we develop a decision tree model that establishes interpretable DR screening policies by transforming
the complex, POMDP-driven personalized screening policies into policies that are more explainable, implementable, and adoptable in clinical practice.</span><span style="font-size:11.0pt"><o:p></o:p></span></p>
</td>
</tr>
</tbody>
</table>
</div>
</td>
</tr>
<tr>
<td style="padding:0in 0in 0in 0in">
<p class="MsoNormal"><span style="font-size:11.0pt;font-family:"Arial",sans-serif"><img width="600" height="82" style="width:6.25in;height:.8541in" id="Picture_x0020_1" src="cid:image002.png@01D9B638.100AFE40" alt="Engineered For What's Next"></span><span style="font-size:11.0pt"><o:p></o:p></span></p>
</td>
</tr>
</tbody>
</table>
</div>
<p class="MsoNormal"><o:p> </o:p></p>
</div>
</body>
</html>